NCT01848067View on ClinicalTrials.gov

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 14, 2013

Primary Completion Date

March 3, 2015

Study Completion Date

June 23, 2016

Conditions
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

Alisertib

Given PO

DRUG

Abiraterone acetate

Given PO

DRUG

Prednisone

Given PO

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

All Listed Sponsors
collaborator

Millennium: The Takeda Oncology Company

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT01848067 - Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter